Biotechnology · Boston, Massachusetts, United States
$28.91
-2.59% (-$0.77)2026-07-10
Smart-Money SignalNeutral · 46/100— Insiders are net sellers over 90 days (-$2.9M, 30 sales vs 14 buys)
Net Income-$56.2M
EPS$-0.93
Market Cap$1.9B
Price Performance
Historical data including institutional events
Company Profile
C
Claire Mazumdar Clemon
CEO & Executive Director
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors.
The company was incorporated in 2018 and is based in Boston, Massachusetts.
